Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

Delayed Quote. Delayed  - 08/24 10:00:00 pm
405.25 USD   -3.65%
08/22 S&P 500 MOVERS : Mro, regn
08/22 REGENERON PHARM : Announces Agreement with BARDA for the Manufacturi..
08/05DJREGENERON PHARM : Revenue Jumps on Sales of Eye Treatment Eylea -- U..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CEST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
08/22 S&P 500 MOVERS : Mro, regn
08/22 REGENERON PHARMACEUTICALS : Announces Agreement with BARDA for the Manufacturing..
08/18 REGENERON PHARMACEUTICALS : Findings from Regeneron Pharmaceuticals Inc. Update ..
08/18 REGENERON PHARMACEUTICALS : U.S. Patents Awarded to Inventors in New Jersey (Aug..
08/18 REGENERON PHARMACEUTICALS : Patent Issued for Promoter-Regulated Differentiation..
08/18 REGENERON PHARMACEUTICALS : Patent Issued for Methods of Inhibiting Tumor Growth..
08/18 REGENERON PHARMACEUTICALS : Assigned Patent
08/11 REGENERON PHARMACEUTICALS : and Adicet Bio Announce Strategic Collaboration to D..
08/05DJREGENERON PHARMACEUTICALS : Revenue Jumps on Sales of Eye Treatment Eylea -- Upd..
08/05DJREGENERON PHARMACEUTICALS : Correction to Regeneron's Revenue on Thursday
More news
Sector news : Bio Therapeutic Drugs
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/23 Who's Next After Medivation?
08/22 Amgen undeterred with cholesterol fighter Repatha; 11 abstracts on tap for up..
08/22 Regeneron inks development deal with BARDA for MERS treatment candidates
08/16 SNIPPET ROUNDUP : Biogen Buy Rumours, CVS Cuts And Spark Gains On Shire's Loss
08/12 Healthcare ratings roundup - upgrades/downgrades
Advertisement
Financials ($)
Sales 2016 5 062 M
EBIT 2016 1 819 M
Net income 2016 731 M
Finance 2016 961 M
Yield 2016 -
P/E ratio 2016 66,56
P/E ratio 2017 45,67
EV / Sales 2016 8,24x
EV / Sales 2017 6,85x
Capitalization 42 671 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 467 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-25.35%42 671
AMGEN, INC.5.24%127 850
GILEAD SCIENCES, INC.-20.45%106 233
CELGENE CORPORATION-7.65%85 728
VERTEX PHARMACEUTICALS..-23.14%23 963
ACTELION LTD17.62%18 399
More Results